Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease

Patient Preference and Adherence

Volumn 5, Issue , 2011, Pages 57-64

  Robottom, Bradley J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Efficacy; Monoamine oxidase inhibitors; Parkinson's disease; Rasagiline; Safety; Selegiline

Indexed keywords

ANTIPARKINSON AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PLACEBO; RASAGILINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE;

ANXIETY; BALANCE DISORDER; BRADYKINESIA; CHEESE; CONFUSION; DISABILITY; DISEASE ACTIVITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FOOD DRUG INTERACTION; HALLUCINATION; HUMAN; HYPERTENSIVE CRISIS; INFECTION; MONOTHERAPY; NAUSEA; NEUROPROTECTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PAIN; PARKINSON DISEASE; PARKINSONISM; PATIENT COMPLIANCE; PATIENT PREFERENCE; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; QUALITY OF LIFE; RED WINE; REVIEW; RIGIDITY; SEROTONIN SYNDROME; SIDE EFFECT; SLEEP DISORDER; SYMPTOM; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84856250996     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S11182     Document Type: Review

References (94)

1. Tanner CM, Aston DA. Epidemiology of Parkinson's disease and akinetic syndromes. Curr Opin Neurol. 2000;13:427.
2. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for parkinson's disease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002;58(1):11-17.
3. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidencebased review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983-995.
4. Hoffman BB, Lefkowitz RJ. Catecholamines, sympoathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Goodman Gilman A, et al, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996:199-248.
5. Rajput A, Zesiewicz TA, Hauser RA. Monoamine oxidase inhibitors. In: Factor SA, Weiner WJ, editors. Parkinson's Disease: Diagnosis and Clinical Management. New York: Demos Medical Publishing; 2008:499-513.
6. Fowler CJ, Tipton KF. On the substrate specificities of the two forms of monoamine oxidase. J Pharm Pharmacol. 1984;36(2):111-115.
7. Rohatagi S, Barrett JS, deWitt KE, Morales RJ. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharm Drug Dispos. 1997;18(7): 567-584.
8. Doller HJ, Connor JD. Changes in neostriatal dopamine concentrations in response to levodopa infusions. J Neurochem. 1980; 34(5):1264-1269.
9. Lewitt PA. MAO-B inhibitor know-how: back to the pharm. Neurology. 2009;72(15):1352-1357.
10. Goetz CG, Stebbins GT, Chmura TA, et al. Teaching tape for the motor section of the unified Parkinson's Disease Rating Scale. Mov Disord. 1995;10(3):263-266.
11. Shulman LM, Gruber-Baldini AL, Anderson KE, et al. The clinically important difference on the unified Parkinson's Disease Rating Scale. Arch Neurol. 2010;67(1):64-70.
12. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000;23(2):75-81.
13. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med. 1993;328(3):176-183.
14. Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology. 1998;51(2):520-525.
15. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 1989;245(4917):519-522.
16. Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline in de novo parkinsonian patients: The Finnish Study. Mov Disord. 1993; 8 Suppl 1:S41-S44.
17. Clarke A. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J Neural Transm. 2003;110(11):1257.
18. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol. 2002;59(12):1937-1943.
19. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed- start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009; 361(13):1268-1278.
20. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed- start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009; 361(13):1268-1278.
21. Heinonen EH, Rinne UK. Selegiline in the treatment of Parkinson's disease. Acta Neurol Scand Suppl. 1989;126:103-111.
22. Lees AJ. Current controversies in the use of selegiline hydrochloride. J Neural Transm Suppl. 1987;25:157-162.
23. Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol. 1988;11(1):45-55.
24. Waters CH, Sethi KD, Hauser RA, et al. Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord. 2004;19(4):426-432.
25. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo- controlled extension of the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism Trial. Ann Neurol. 2002;51(5): 604-612.
26. Lieberman AN, Gopinathan G, Neophytides A, Foo SH. Deprenyl versus placebo in Parkinson disease: a double-blind study. NY State J Med. 1987;87(12):646-649.
27. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62(2): 241-248.
28. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting Effect in Adjunct Therapy with Rasagiline Given Once Daily Study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365(9463):947-954.
29. Shulman LM, Gruber-Baldini AL, Anderson KE, et al. The evolution of disability in Parkinson disease. Mov Disord. 2008;23(6):790-796.
30. Schawab RS, England AC Jr. Parkinson's disease: rehabilitation aspects. Rehabil Lit. 1961;22:326-336.
31. Heinonen EH, Rinne UK, Tuominen J. Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment. Acta Neurol Scand Suppl. 1989;126: 113-118.
32. Larsen JP, Boas J. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: An interim analysis of a Norwegian-Danish 5-year study. Norwegian-Danish Study Group. Mov Disord. 1997;12(2):175-182.
33. Webster DD. Critical analysis of the disability in Parkinson's disease. Mod Treat. 1968;5(2):257-282.
34. Canter C, de la Torre R, Mier M. A method of evaluating disabilities in patients with Parkinson's disease. J Nerv Ment Dis. 1961; 133:143-147.
35. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ. 1995;311(7020):1602-1607.
36. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome C from mitochondria: a primary site for bcl-2 regulation of apoptosis. Science. 1997;275(5303):1132-1136.
37. Shahani N, Gourie-Devi M, Nalini A, et al. (-)-Deprenyl alleviates the degenerative changes induced in the neonatal rat spinal cord by CSF from amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(3):172-179.
38. Carrillo MC, Minami C, Kitani K, et al. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci. 2000;67(5):577-585.
39. Maruyama W, Yamamoto T, Kitani K, et al. Mechanism underlying anti- apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech Ageing Dev. 2000;116(2-3):181-191.
40. Takahata K, Shimazu S, Katsuki H, et al. Effects of selegiline on antioxidant systems in the nigrostriatum in rat. J Neural Transm. 2006; 113(2):151-158.
41. Finberg JP, Takeshima T, Johnston JM, Commissiong JW. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport. 1998;9(4):703-707.
42. Maruyama W, Akao Y, Carrillo MC, et al. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 2002; 24(5):675-682.
43. Sharma SK, Carlson EC, Ebadi M. Neuroprotective actions of selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons. J Neurocytol. 2003;32(4):329-343.
44. Ebadi M, Sharma S, Shavali S, et al. The multiple actions of selegiline. Proc West Pharmacol Soc. 2002;45:39-41.
45. Blandini F. Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease? CNS Drug Rev. 2005;11(2):183-194.
46. Kupsch A, Sautter J, Gotz ME, et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm. 2001; 108(8-9):985-1009.
47. Blandini F, Armentero MT, Fancellu R, et al. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol. 2004; 187(2):455-459.
48. Simon L, Szilagyi G, Bori Z, et al. (-)-D-deprenyl attenuates apoptosis in experimental brain ischaemia. Eur J Pharmacol. 2001; 430(2-3):235-241.
49. Speiser Z, Mayk A, Eliash S, Cohen S. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm. 1999;106(7-8):593-606.
50. Holford NH, Chan PL, Nutt JG, et al. Parkinson Study Group. Disease progression and pharmacodynamics in Parkinson disease: evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn. 2006;33(3):281-311.
51. D'Agostino RB. The delayed-start study design. N Engl J Med. 2009;361(13):1304-1306.
52. Olanow CW, Rascol O. The delayed-start study in Parkinson disease: can't satisfy everyone. Neurology. 2010;74(14):1149-1150.
53. Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology. 2010;74(14): 1143-1148.
54. Ahlskog JE, Uitti RJ. Reply to Drs. Olanow and Rascol. Neurology. 2010;74(14):1151.
55. Sampaio C, Ferreira JJ. Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression. Nat Rev Neurol. 2010;6(3): 126-128.
56. Mehta SH, Morgan JC, Sethi KD. Does rasagiline have a disease- modifying effect on Parkinson's disease? Curr Neurol Neurosci Rep. 2010;10(6):413-416.
57. Heinonen EH. Safety of selegiline (deprenyl) in the treatment of Parkinsons disease. Drug Safety. 1998;19(1):11.
58. Myllyla VV, Sotaniemi K, Maki-Ikola O, et al. Role of selegiline in combination therapy of Parkinson's disease. Neurology. 1996 Dec; 47(6 Suppl 3):S200-S209.
59. Elizan TS, Moros DA, Yahr MD. Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease: experience in 26 patients receiving combined therapy for 26 months. Arch Neurol. 1991;48(1):31-34.
60. Golbe LI. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease. Neurology. 1989;39(8):1109-1111.
61. Waters CH. Side effects of selegiline (eldepryl). J Geriatr Psychiatry Neurol. 1992;5(1):31-34.
62. Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;63(2):228-234.
63. Goetz CG, Schwid SR, Eberly SW, et al; Parkinson Study Group TEMPO and PRESTO Investigators. Safety of rasagiline in elderly patients with Parkinson disease. Neurology. 2006;66(9):1427-1429.
64. Leegwater-Kim J, Bortan E. The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging. 2010;5:149-156.
65. Marley E, Blackwell B. Interactions of monoamine oxidase inhibitors, amines, and foodstuffs. Adv Pharmacol Chemother. 1970;8:185-349.
66. Elsworth JD, Glover V, Reynolds GP, et al. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the'cheese effect'. Psychopharmacology (Berl). 1978;57(1):33-38.
67. Schulz R. Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther. 1989; 46(5):528.
68. Heinonen EH, Lammintausta R. A review of the pharmacology of selegiline. Acta Neurol Scand Suppl. 1991;136:44-59.
69. Goren T. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. J Clin Pharmacol. 2010;50(12):1420-1428.
70. deMarcaida JA. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord. 2006;21(10):1716.
71. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6): 705-713.
72. Radomski JW, Dursun SM, Reveley MA, Kutcher SP. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses. 2000; 55(3): 218-224.
73. Oates JA, Sjoerdsma A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology. 1960; 10:1076-1078.
74. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000; 79(4):201-209.
75. Waters CH. Fluoxetine and selegiline: lack of significant interaction. Can J Neurol Sci. 1994;21(3):259-261.
76. Feighner JP, Boyer WF, Tyler DL, Neborsky RJ. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry. 1990; 51(6):222-225.
77. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology. 1997;48(4):1070-1077.
78. Hilli J, Korhonen T, Laine K. Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1526-1532.
79. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord. 2004;19(4):397-405.
80. Evans AH, Lawrence AD, Cresswell SA, et al. Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti- reward. Mov Disord. 2010;25(7):867-876.
81. Evans AH, Lawrence AD, Potts J, et al. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology. 2005;65(10):1570-1574.
82. Giovannoni G, O'Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68(4):423-428.
83. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol. 2003;2(10):595-604.
84. Grosset D, European PD Therapy Compliance Study Group. Therapy adherence issues in Parkinson's disease. J Neurol Sci. 2010; 289(1-2):115-118.
85. Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter european study. Mov Disord. 2009; 24(6):826-832.
86. Olanow CW, Obeso JA, Stocchi F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol. 2006;2(7):382-392.
87. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol. 2005; 62(6):905-910.
88. Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord. 2009; 24(6):826-832.
89. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice parameter: treatment of nonmotor symptoms of Parkinson disease. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74(11):924-931.
90. Gruber-Baldini AL, Ye J, Anderson KE, Shulman LM. Effects of optimism/pessimism and locus of control on disability and quality of life in Parkinson's disease. Parkinsonism Relat Disord. 2009; 15(9):665-669.
91. Bryson HM, Milne RJ, Chrisp P. Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease. Pharmacoeconomics. 1992;2(2):118-136.
92. Lyons KE, Friedman JH, Hermanowicz N, et al. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clin Neuropharmacol. 2010;33(1):5-10.
93. Biglan KM, Schwid S, Eberly S, et al. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord. 2006; 21(5):616-623.
94. Jost WH, Klasser M, Reichmann H. Rasagiline in daily clinical use: results of a treatment study of Parkinson patients with a combination treatment. Fortschr Neurol Psychiatr. 2008;76(10):594-599.